TY - JOUR
T1 - Ibuprofen lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates.
AU - De Carolis, Maria Pia
AU - Bersani, Iliana
AU - De Rosa, Gabriella
AU - Cota, Francesco
AU - Romagnoli, Costantino
PY - 2012
Y1 - 2012
N2 - This retrospective, study compared the efficacy and safety of Ibuprofen-Lysinate (Arfen, intramuscular formulation, Group I, n=156) used during 2000-2005 and Sodium-ibuprofen (Pedea, intravenous solution, Group II, n=60) used during 2006-2008, for the prophylaxis of Patent Ductus Arteriosus in inborn neonates with gestational age ≤ 28 weeks. Ductus closure rate after prophylaxis was significantly higher (73.1% vs 50%; P=0.002) and surgical ligation significantly lower (8.2% vs 23.3%; P=0.005) in Group I. A smaller number of neonates of Group I vs Group II showed oliguria and hemorrhagic disease.
AB - This retrospective, study compared the efficacy and safety of Ibuprofen-Lysinate (Arfen, intramuscular formulation, Group I, n=156) used during 2000-2005 and Sodium-ibuprofen (Pedea, intravenous solution, Group II, n=60) used during 2006-2008, for the prophylaxis of Patent Ductus Arteriosus in inborn neonates with gestational age ≤ 28 weeks. Ductus closure rate after prophylaxis was significantly higher (73.1% vs 50%; P=0.002) and surgical ligation significantly lower (8.2% vs 23.3%; P=0.005) in Group I. A smaller number of neonates of Group I vs Group II showed oliguria and hemorrhagic disease.
KW - prophylaxis of patent ductus
KW - prophylaxis of patent ductus
UR - http://hdl.handle.net/10807/23599
M3 - Article
SN - 0019-6061
SP - 47
EP - 49
JO - Indian Pediatrics
JF - Indian Pediatrics
ER -